|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al TAX 324 Study Group: Cisplatin and
fluorouracil alone or with docetaxel in head and neck cancer. N
Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim YC, Oh SY, Cha YY, Kim SH, Jin X and
Kim H: Cancer stem cell traits in squamospheres derived from
primary head and neck squamous cell carcinomas. Oral Oncol.
47:83–91. 2011. View Article : Google Scholar
|
|
9
|
Oh SY, Kang HJ, Kim YS, Kim H and Lim YC:
CD44-negative cells in head and neck squamous carcinoma also have
stem-cell like traits. Eur J Cancer. 49:272–280. 2013. View Article : Google Scholar
|
|
10
|
Li F, Tiede B, Massagué J and Kang Y:
Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res.
17:3–14. 2007. View Article : Google Scholar
|
|
11
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lim YC, Kang HJ, Kim YS and Choi EC:
All-trans-retinoic acid inhibits growth of head and neck cancer
stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer.
48:3310–3318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee SH, Nam HJ, Kang HJ, Kwon HW and Lim
YC: Epigallocatechin-3-gallate attenuates head and neck cancer stem
cell traits through suppression of Notch pathway. Eur J Cancer.
49:3210–3218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Atkinson RL and Rosen JM:
Selective targeting of radiation-resistant tumor-initiating cells.
Proc Natl Acad Sci USA. 107:3522–3527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar :
|
|
17
|
Portela A and Esteller M: Epigenetic
modifications and human disease. Nat Biotechnol. 28:1057–1068.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haberland M, Montgomery RL and Olson EN:
The many roles of histone deacetylases in development and
physiology: Implications for disease and therapy. Nat Rev Genet.
10:32–42. 2009. View
Article : Google Scholar
|
|
19
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: Causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar
|
|
20
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG,
et al: Valproic acid defines a novel class of HDAC inhibitors
inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu P, Martin E, Mengwasser J, Schlag P,
Janssen KP and Göttlicher M: Induction of HDAC2 expression upon
loss of APC in colorectal tumorigenesis. Cancer Cell. 5:455–463.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ropero S, Fraga MF, Ballestar E, Hamelin
R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F,
Paz MF, et al: A truncating mutation of HDAC2 in human cancers
confers resistance to histone deacetylase inhibition. Nat Genet.
38:566–569. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giudice FS, Pinto DS Jr, Nör JE, Squarize
CH and Castilho RM: Inhibition of histone deacetylase impacts
cancer stem cells and induces epithelial-mesenchyme transition of
head and neck cancer. PLoS One. 8:e586722013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carew JS, Giles FJ and Nawrocki ST:
Histone deacetylase inhibitors: Mechanisms of cell death and
promise in combination cancer therapy. Cancer Lett. 269:7–17. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Erlich RB, Rickwood D, Coman WB, Saunders
NA and Guminski A: Valproic acid as a therapeutic agent for head
and neck squamous cell carcinomas. Cancer Chemother Pharmacol.
63:381–389. 2009. View Article : Google Scholar
|
|
29
|
Starkova J, Madzo J, Cario G, Kalina T,
Ford A, Zaliova M, Hrusak O and Trka J: The identification of
(ETV6)/RUNX1-regulated genes in lymphopoiesis using histone
deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic
cells. Clin Cancer Res. 13:1726–1735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cinatl J Jr, Cinatl J, Driever PH,
Kotchetkov R, Pouckova P, Kornhuber B and Schwabe D: Sodium
valproate inhibits in vivo growth of human neuroblastoma cells.
Anticancer Drugs. 8:958–963. 1997. View Article : Google Scholar
|
|
31
|
Blaheta RA, Michaelis M, Driever PH and
Cinatl J Jr: Evolving anticancer drug valproic acid: Insights into
the mechanism and clinical studies. Med Res Rev. 25:383–397. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zapotocky M, Mejstrikova E, Smetana K,
Stary J, Trka J and Starkova J: Valproic acid triggers
differentiation and apoptosis in AML1/ETO-positive leukemic cells
specifically. Cancer Lett. 319:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hrebackova J, Hrabeta J and Eckschlager T:
Valproic acid in the complex therapy of malignant tumors. Curr Drug
Targets. 11:361–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Witt D, Burfeind P, von Hardenberg S,
Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen
J and Kaulfuss S: Valproic acid inhibits the proliferation of
cancer cells by re-expressing cyclin D2. Carcinogenesis.
34:1115–1124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gan CP, Hamid S, Hor SY, Zain RB, Ismail
SM, Wan Mustafa WM, Teo SH, Saunders N and Cheong SC: Valproic
acid: Growth inhibition of head and neck cancer by induction of
terminal differentiation and senescence. Head Neck. 34:344–353.
2012. View Article : Google Scholar
|
|
36
|
Khalil MA, Hrabeta J, Cipro S, Stiborova
M, Vicha A and Eckschlager T: Neuroblastoma stem cells - mechanisms
of chemoresistance and histone deacetylase inhibitors. Neoplasma.
59:737–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee S, Park JR, Seo MS, Roh KH, Park SB,
Hwang JW, Sun B, Seo K, Lee YS, Kang SK, et al: Histone deacetylase
inhibitors decrease proliferation potential and multilineage
differentiation capability of human mesenchymal stem cells. Cell
Prolif. 42:711–720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gurvich N, Tsygankova OM, Meinkoth JL and
Klein PS: Histone deacetylase is a target of valproic acid-mediated
cellular differentiation. Cancer Res. 64:1079–1086. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chou CW, Wu MS, Huang WC and Chen CC: HDAC
inhibition decreases the expression of EGFR in colorectal cancer
cells. PLoS One. 6:e180872011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang XH, Meng XW, Sun X, Liu BR, Han MZ,
Du YJ, Song YY and Xu W: Wnt/β-catenin signaling regulates MAPK and
Akt1 expression and growth of hepatocellular carcinoma cells.
Neoplasma. 58:239–244. 2011. View Article : Google Scholar
|
|
41
|
De Sarno P, Li X and Jope RS: Regulation
of Akt and glycogen synthase kinase-3 beta phosphorylation by
sodium valproate and lithium. Neuropharmacology. 43:1158–1164.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Graff JR, Herman JG, Lapidus RG, Chopra H,
Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB:
E-cadherin expression is silenced by DNA hypermethylation in human
breast and prostate carcinomas. Cancer Res. 55:5195–5199.
1995.PubMed/NCBI
|
